



EXECUTIVE CHAMBERS  
HONOLULU

DAVID Y. IGE  
GOVERNOR

July 10, 2017

**GOV. MSG. NO. 1256**

The Honorable Ronald D. Kouchi,  
President  
and Members of the Senate  
Twenty-Ninth State Legislature  
State Capitol, Room 409  
Honolulu, Hawai'i 96813

The Honorable Scott K. Saiki,  
Speaker and Members of the  
House of Representatives  
Twenty-Ninth State Legislature  
State Capitol, Room 431  
Honolulu, Hawai'i 96813

Dear President Kouchi, Speaker Saiki, and Members of the Legislature:

This is to inform you that on July 10, 2017, the following bill was signed into law:

SB997 SD1 HD2 CD1

RELATING TO THE UNIFORM CONTROLLED  
SUBSTANCES ACT  
**ACT 155 (17)**

Sincerely,

DAVID Y. IGE  
Governor, State of Hawai'i

---

---

# A BILL FOR AN ACT

RELATING TO THE UNIFORM CONTROLLED SUBSTANCES ACT.

**BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:**

1 SECTION 1. Section 329-14, Hawaii Revised Statutes, is  
2 amended as follows:

3 1. By amending subsection (b) to read:

4 "(b) Any of the following opiates, including their  
5 isomers, esters, ethers, salts, and salts of isomers, esters,  
6 and ethers, unless specifically excepted, whenever the existence  
7 of these isomers, esters, ethers, and salts is possible within  
8 the specific chemical designation:

9 (1) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-  
10 phenethyl)-4-piperidinyl]-N-phenylacetamide);

11 (2) Acetylmethadol;

12 (3) Allylprodine;

13 (4) Alphacetylmethadol (except levo-alphacetylmethadol,  
14 levomethadyl acetate, or LAAM);

15 (5) Alphameprodine;

16 (6) Alphamethadol;



- 1 (7) Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-
- 2 phenyl)ethyl-4-piperidyl] propionanilide; 1-(1-methyl-
- 3 2-phenylethyl)-4-(N-propanilido) piperidine);
- 4 (8) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-
- 5 thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);
- 6 (9) Benzethidine;
- 7 (10) Betacetylmethadol;
- 8 (11) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-
- 9 piperidinyl]-N-phenylpropanamide);
- 10 (12) Beta-hydroxy-3-methylfentanyl (N-[1-(2-hydroxy-2-
- 11 phenethyl)-3-methyl-4-piperidinyl]-N-
- 12 phenylpropanamide);
- 13 (13) Betameprodine;
- 14 (14) Betamethadol;
- 15 (15) Betaprodine;
- 16 (16) Clonitazene;
- 17 (17) Dextromoramide;
- 18 (18) Diampromide;
- 19 (19) Diethylthiambutene;
- 20 (20) Difenoxyin;
- 21 (21) Dimenoxadol;



- 1 (22) Dimepheptanol;
- 2 (23) Dimethylthiambutene;
- 3 (24) Dioxaphetyl butyrate;
- 4 (25) Dipipanone;
- 5 (26) Ethylmethylthiambutene;
- 6 (27) Etonitazene;
- 7 (28) Etoxeridine;
- 8 (29) Furethidine;
- 9 (30) Hydroxypethidine;
- 10 (31) Ketobemidone;
- 11 (32) Levomoramide;
- 12 (33) Levophenacylmorphan;
- 13 (34) 3-Methylfentanyl (N-[3-methyl-1-(2-phenylethyl)-4-
- 14 piperidyl]-N-phenylpropanamide);
- 15 (35) 3-methylthiofentanyl (N-[3-methyl-1-(2-thienyl)ethyl-
- 16 4-piperidinyl]-N-phenylpropanamide);
- 17 (36) Morpheridine;
- 18 (37) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
- 19 (38) Noracymethadol;
- 20 (39) Norlevorphanol;
- 21 (40) Normethadone;



- 1 (41) Norpipanone;
- 2 (42) Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-
- 3 phenethyl)-4-piperidinyl] propanamide;
- 4 (43) PEPAP (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine;
- 5 (44) Phenadoxone;
- 6 (45) Phenampromide;
- 7 (46) Phenomorphan;
- 8 (47) Phenoperidine;
- 9 (48) Piritramide;
- 10 (49) Proheptazine;
- 11 (50) Properidine;
- 12 (51) Propiram;
- 13 (52) Racemoramide;
- 14 (53) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-
- 15 piperidinyl]-propanamide);
- 16 (54) Tilidine;
- 17 (55) Trimeperidine;
- 18 (56) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
- 19 (benzylfentanyl), its optical isomers, salts, and
- 20 salts of isomers;



- 1 (57) N-[1-(2-thienyl)methyl-4-piperidyl]-N-  
2 phenylpropanamide (thenylfentanyl), its optical  
3 isomers, salts, and salts of isomers; [and]
- 4 (58) N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide,  
5 (acetyl fentanyl), its optical, positional, and  
6 geometric isomers, salts, and salts of isomers[-];
- 7 (59) AH-7921 (3,4-dichloro-N-[(1-dimethylamino)  
8 cyclohexylmethyl]benzamide), its isomers, esters,  
9 ethers, salts, and salts of isomers, esters, and  
10 ethers;
- 11 (60) N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide, its  
12 isomers, esters, ethers, salts, and salts of isomers,  
13 esters, and ethers (Other names: Butyryl fentanyl);
- 14 (61) N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-  
15 yl]-N-phenylpropionamide, its isomers, esters, ethers,  
16 salts, and salts of isomers, esters, and ethers (Other  
17 names: beta-hydroxythiofentanyl);
- 18 (62) N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-  
19 carboxamide, its isomers, esters, ethers, salts, and  
20 salts of isomers, esters, and ethers (other names:  
21 Furanyl fentanyl); and



1        (63) 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-  
2        methylbenzamide, its isomers, esters, ethers, salts,  
3        and salts of isomers, esters, and ethers (Other names:  
4        U-47700)."

5        2. By amending subsection (g) to read:

6        "(g) Any of the following cannabinoids, their salts,  
7        isomers, and salts of isomers, unless specifically excepted,  
8        whenever the existence of these salts, isomers, and salts of  
9        isomers is possible within the specific chemical designation:

10       (1) Tetrahydrocannabinols; meaning tetrahydrocannabinols  
11       naturally contained in a plant of the genus Cannabis  
12       (cannabis plant), as well as synthetic equivalents of  
13       the substances contained in the plant, or in the  
14       resinous extractives of Cannabis, sp. or synthetic  
15       substances, derivatives, and their isomers with  
16       similar chemical structure and pharmacological  
17       activity to those substances contained in the plant,  
18       such as the following: Delta 1 cis or trans  
19       tetrahydrocannabinol, and their optical isomers; Delta  
20       6 cis or trans tetrahydrocannabinol, and their optical  
21       isomers; and Delta 3,4 cis or trans-



1 tetrahydrocannabinol, and its optical isomers (since  
2 nomenclature of these substances is not  
3 internationally standardized, compounds of these  
4 structures, regardless of numerical designation of  
5 atomic positions, are covered);

6 (2) Naphthoylindoles; meaning any compound containing a 3-  
7 (1-naphthoyl)indole structure with substitution at the  
8 nitrogen atom of the indole ring by a alkyl,  
9 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,  
10 1-(N-methyl-2-piperidinyl)methyl or 2-(4-  
11 morpholinyl)ethyl group, whether or not further  
12 substituted in the indole ring to any extent and  
13 whether or not substituted in the naphthyl ring to any  
14 extent;

15 (3) Naphthylmethylinindoles; meaning any compound containing  
16 a 1H-indol-3-yl-(1-naphthyl) methane structure with  
17 substitution at the nitrogen atom of the indole ring  
18 by a alkyl, haloalkyl, alkenyl, cycloalkylmethyl,  
19 cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or  
20 2-(4-morpholinyl) ethyl group whether or not further  
21 substituted in the indole ring to any extent and





- 1           whether or not substituted in the naphthyl ring to any  
2           extent;
- 3           (4) Naphthoylpyrroles; meaning any compound containing a  
4           3-(1-naphthoyl)pyrrole structure with substitution at  
5           the nitrogen atom of the pyrrole ring by a alkyl,  
6           haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,  
7           1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)  
8           ethyl group whether or not further substituted in the  
9           pyrrole ring to any extent, whether or not substituted  
10          in the naphthyl ring to any extent;
- 11          (5) Naphthylmethylindenes; meaning any compound containing  
12          a naphthylideneindene structure with substitution at  
13          the 3-position of the indene ring by a alkyl,  
14          haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,  
15          1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl)  
16          ethyl group whether or not further substituted in the  
17          indene ring to any extent, whether or not substituted  
18          in the naphthyl ring to any extent;
- 19          (6) Phenylacetylindoles; meaning any compound containing a  
20          3-phenylacetylindole structure with substitution at  
21          the nitrogen atom of the indole ring by a alkyl,



- 1 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,  
2 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl)  
3 ethyl group whether or not further substituted in the  
4 indole ring to any extent, whether or not substituted  
5 in the phenyl ring to any extent;
- 6 (7) Cyclohexylphenols; meaning any compound containing a  
7 2-(3-hydroxycyclohexyl) phenol structure with  
8 substitution at the 5-position of the phenolic ring by  
9 a alkyl, haloalkyl, alkenyl, cycloalkylmethyl,  
10 cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or  
11 2-(4-morpholinyl) ethyl group whether or not  
12 substituted in the cyclohexyl ring to any extent;
- 13 (8) Benzoylindoles; meaning any compound containing a 3-  
14 (benzoyl) indole structure with substitution at the  
15 nitrogen atom of the indole ring by a alkyl,  
16 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,  
17 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-  
18 morpholinyl) ethyl group whether or not further  
19 substituted in the indole ring to any extent and  
20 whether or not substituted in the phenyl ring to any  
21 extent;



- 1 (9) 2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)  
2 pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-  
3 naphthalenylmethanone (another trade name is WIN  
4 55,212-2);
- 5 (10) (6a,10a)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-  
6 methyloctan-2-yl)-6a,7,10,10a-  
7 tetrahydrobenzo[c]chromen-1-ol (other trade names are:  
8 HU-210/HU-211);
- 9 (11) Tetramethylcyclopropanoylindoles; meaning any compound  
10 containing a 3-tetramethylcyclopropanoylindole  
11 structure with substitution at the nitrogen atom of  
12 the indole ring by an alkyl, haloalkyl, cyanoalkyl,  
13 alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-  
14 methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl,  
15 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-  
16 morpholinyl)methyl, or tetrahydropyranylmethyl group,  
17 whether or not further substituted in the indole ring  
18 to any extent and whether or not substituted in the  
19 tetramethylcyclopropyl ring to any extent;



- 1 (12) N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide,  
2 its optical, positional, and geometric isomers, salts,  
3 and salts of isomers (Other names: APINACA, AKB48);
- 4 (13) Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate, its  
5 optical, positional, and geometric isomers, salts, and  
6 salts of isomers (Other names: PB-22; QUPIC);
- 7 (14) Quinolin-8-yl 1-(5fluoropentyl)-1H-indole-3-  
8 carboxylate, its optical, positional, and geometric  
9 isomers, salts, and salts of isomers (Other names: 5-  
10 fluoro-PB-22; 5F-PB-22);
- 11 (15) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-  
12 fluorobenzyl)-1H-indazole-3-carboxamide, its optical,  
13 positional, and geometric isomers, salts, and salts of  
14 isomers (Other names: AB-FUBINACA);
- 15 (16) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-  
16 indazole-3-carboxamide, its optical, positional, and  
17 geometric isomers, salts, and salts of isomers (Other  
18 names: ADB-PINACA);
- 19 (17) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-  
20 (cyclohexylmethyl)-1H-indazole-3-carboxamide, its



- 1 optical, positional, and geometric isomers, salts, and  
2 salts of isomers (Other names: AB-CHMINACA);
- 3 (18) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-  
4 indazole-3-carboxamide, and geometric isomers, salts,  
5 and salts of isomers (Other names: AB-PINACA);
- 6 (19) [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-  
7 yl)methanone, and geometric isomers, salts, and salts  
8 of isomers (Other names: THJ-2201);
- 9 (20) Methyl (1-(4-fluorobenzyl)-1 H-indazole-3-carbonyl)-L-  
10 valinate, and geometric isomers, salts, and salts of  
11 isomers (Other names: FUB-AMB);
- 12 (21) (S)-methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-  
13 carboxamido)-3-methylbutanoate, and geometric isomers,  
14 salts, and salts of isomers (Other names: 5-fluoro-  
15 AMB, 5-fluoro-AMP);
- 16 (22) N-((3s,5s,7s)-adamantan-1-yl)-1-(5-fluoropentyl)-1H-  
17 indazole-3-carboxamide, and geometric isomers, salts,  
18 and salts of isomers (Other names: AKB48 N-(5-  
19 fluoropentyl) analog, 5F-AKB48, APINACA 5-fluoropentyl  
20 analog, 5F-APINACA);



1 (23) N-adamantyl-1-fluoropentylindole-3-Carboxamide, and  
2 geometric isomers, salts, and salts of isomers (Other  
3 names: STS-135, 5F-APICA; 5-fluoro-APICA);

4 (24) [~~Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-~~  
5 ~~carboxylate,~~] Naphthalen-1-yl 1-(5-fluoropentyl)-1H-  
6 indole-3-carboxylate, and geometric isomers, salts,  
7 and salts of isomers (Other names: NM2201); [~~and~~]

8 (25) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-  
9 (cyclohexylmethyl)-1H-indazole-3-carboxamide, and  
10 geometric isomers, salts, and salts of isomers (Other  
11 names: MAB-CHMINACA and ADB-CHMINACA) [-]; and

12 (26) Methyl 2-[1-(5-fluoropentyl)-1H-indazole-3-  
13 carboxamido]-3,3-dimethylbutanoate (other names: 5F-  
14 ADB, 5-flouro-ADB, and 5F-MDMB-PINACA), its optical,  
15 positional, and geometric isomers, salts, and salts of  
16 isomers."

17 SECTION 2. Section 329-16, Hawaii Revised Statutes, is  
18 amended by amending subsection (c) to read as follows:

19 "(c) Any of the following opiates, including their  
20 isomers, esters, ethers, salts, and salts of isomers, whenever



1 the existence of these isomers, esters, ethers, and salts is  
2 possible within the specific chemical designation:

- 3 (1) Alfentanil;
- 4 (2) Alphaprodine;
- 5 (3) Anileridine;
- 6 (4) Bezitramide;
- 7 (5) Bulk Dextropropoxyphene (nondosage form);
- 8 (6) Carfentanil;
- 9 (7) Dihydrocodeine;
- 10 (8) Diphenoxylate;
- 11 (9) Fentanyl;
- 12 (10) Isomethadone;
- 13 (11) Levo-alphaacetylmethadol (LAAM);
- 14 (12) Levomethorphan;
- 15 (13) Levorphanol;
- 16 (14) Metazocine;
- 17 (15) Methadone;
- 18 (16) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-  
19 diphenyl butane;
- 20 (17) Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-  
21 diphenyl-propane-carboxylic acid;



- 1 (18) Pethidine (Meperidine);
- 2 (19) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-
- 3 phenylpiperidine;
- 4 (20) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-
- 5 carboxylate;
- 6 (21) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-
- 7 4-carboxylic acid;
- 8 (22) Phenazocine;
- 9 (23) Piminodine;
- 10 (24) Racemethorphan;
- 11 (25) Racemorphan;
- 12 (26) Remifentanil;
- 13 (27) Sufentanil; [~~and~~]
- 14 (28) Tapentadol[-]; and
- 15 (29) Thiafentanil."

16 SECTION 3. Section 329-22, Hawaii Revised Statutes, is

17 amended by amending subsection (d) to read as follows:

18 "(d) Depressants. Unless specifically exempted or

19 excluded or unless listed in another schedule, any material,

20 compound, mixture, or preparation that contains any quantity of

21 the following substances having a depressant effect on the





1 central nervous system, including its salts, isomers, and salts  
2 of isomers:

- 3 (1) Lacosamide [(R)-2-acetoamido-N-benzyl-3-methoxy-  
4 propionamide], (Vimpat); ~~and~~
- 5 (2) Pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic  
6 acid] [~~-~~]; and
- 7 (3) Brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-  
8 yl]butanamide) (Other names: BRV; UCB-34714; Briviact)  
9 and its salts."

10 SECTION 4. Statutory material to be repealed is bracketed  
11 and stricken. New statutory material is underscored.

12 SECTION 5. This Act shall take effect upon its approval.

APPROVED this 10 day of JUL, 2017



GOVERNOR OF THE STATE OF HAWAII

**THE SENATE OF THE STATE OF HAWAII**

Date: May 2, 2017  
Honolulu, Hawaii 96813

We hereby certify that the foregoing Bill this day passed Final Reading in the  
Senate of the Twenty-ninth Legislature of the State of Hawaii, Regular Session of 2017.



President of the Senate




Clerk of the Senate

SB No. 997, SD 1, HD 2, CD 1


THE HOUSE OF REPRESENTATIVES OF THE STATE OF HAWAII

Date: May 2, 2017  
Honolulu, Hawaii

We hereby certify that the above-referenced Bill on this day passed Final Reading in the House of Representatives of the Twenty-Ninth Legislature of the State of Hawaii, Regular Session of 2017.



Joseph M. Souki  
Speaker  
House of Representatives



Brian L. Takeshita  
Chief Clerk  
House of Representatives